RESP303

Phase 2Small molecule

TThirty Respiratory Limited

RESP303 is one of 3 small molecule programs targeting Pseudomonas Aeruginosa. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pseudomonas AeruginosaActive, not recruiting

Pseudomonas AeruginosaPhase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Pseudomonas Aeruginosa

#DrugCompanyPhaseTrials

AZD0292

AstraZeneca

Phase 2

2 2

RESP303

TThirty Respiratory Limited

Phase 2

1 3

Pseudomonas Aeruginosa

QQilu Hospital of Shandong University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1/2Active, not recruiting

Pseudomonas Aeruginosa

NCT06663176

Clinical

Trials by Indication[1]

Pseudomonas Aeruginosa1 trial

Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa)

Active, not recruiting·TThirty Respiratory Limited·Phase 1/2·NCT06663176·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RESP303. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RESP303 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RESP303. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Thirty Respiratory Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThirty Respiratory Limited

RESP303

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Pseudomonas Aeruginosa1 trial

References

Drug Info

Quick Facts

Related News